Sona Nanotech's THT Cancer Therapy Demonstrates Strong Efficacy And Durability In Combination with Immunotherapy In Peer-reviewed Preclinical Study

• On 7 Apr 2026 Sona Nanotech released peer‑reviewed preclinical data showing that its Targeted Hyperthermia Therapy (THT) combined with a PD‑1 inhibitor achieved 38 % disease‑free survival and complete tumor clearance in 8 of 21 mice in a cold colorectal cancer (CT26) model.
• The study demonstrated that THT can convert immunologically “cold” tumors into responders, with 100 % response to subsequent PD‑1 therapy versus 0 % for PD‑1 alone.
• Results were published in Journal of Nanobiotechnology and are positioned as the scientific basis for the next clinical trial that will pair THT with immunotherapy (building on the earlier first‑in‑human melanoma data).

• Scope: The announcement is a preclinical efficacy update; no new financing, regulatory approval, or commercial launch is involved.
• Comparison to prior expectations: Sona had already signaled that THT could synergize with checkpoint inhibitors. The data confirm the hypothesis and are consistent with the company’s stated development plan.
• Market reaction potential: Because the information was anticipated (the company previously announced intent to explore combos) and is pre‑clinical, the impact on valuation is limited. It may provide a modest upside catalyst for risk‑averse investors awaiting clinical proof, but it does not materially alter cash‑flow forecasts or financing needs.
• Conclusion: The news is positive in substance yet routine relative to prior guidance; therefore classified as Routine – Positive.

Sona Nanotech focuses on Targeted Hyperthermia Therapy (THT) – a photothermal platform that delivers localized heating to tumor tissue, enhancing immune recognition. The flagship THT program has progressed from preclinical validation to an early‑stage first‑in‑human melanoma feasibility study (10 patients) reporting 80 % overall response and 60 % complete responses in biopsied lesions (Oct 2025). Current pipeline emphasis is on combination with checkpoint inhibitors (PD‑1/PD‑L1), leveraging the immunogenic boost observed in animal models.